Free Trial
LON:RENE

ReNeuron Group (RENE) Share Price, News & Analysis

GBX 3.38
-0.08 (-2.17%)
(As of 02/5/2024)
Today's Range
3.28
3.50
50-Day Range
3.38
3.38
52-Week Range
3.28
11.50
Volume
177,373 shs
Average Volume
578,249 shs
Market Capitalization
£1.93 million
P/E Ratio
N/A
Dividend Yield
0.76%
Price Target
N/A
RENE stock logo

About ReNeuron Group Stock (LON:RENE)

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

RENE Stock Price History

RENE Stock News Headlines

I’m giving you the name of this investment for free
What people don’t know is that Roivant is capitalizing on a wealth secret that goes back over a century. There are a few other public companies who are as well. Only you don’t know it… because it’s not something they openly talk about. That’s why I made this presentation. I want to expose you to a wealth-building secret that you deserve to benefit from.
ReNeuron Group PLC RENE
I’m giving you the name of this investment for free
What people don’t know is that Roivant is capitalizing on a wealth secret that goes back over a century. There are a few other public companies who are as well. Only you don’t know it… because it’s not something they openly talk about. That’s why I made this presentation. I want to expose you to a wealth-building secret that you deserve to benefit from.
ReNeuron Group plc (LON:RENE): Is Breakeven Near?
See More Headlines
Receive RENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/20/2020
Today
7/17/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
26
Year Founded
N/A

Profitability

Net Income
£-5,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£783,000.00
Cash Flow
GBX 5.55 per share
Book Value
GBX 4 per share

Miscellaneous

Free Float
N/A
Market Cap
£1.93 million
Optionable
Not Optionable
Beta
0.67
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Iain Gladstone Ross B.Sc. (Age 70)
    BSc (Hons), C.DIR, CH.D, Executive Chairman
    Comp: $430k
  • Dr. John David Sinden B.A. (Age 73)
    BA, M.A., MA, Ph.D., Co-Founder
    Comp: $103k
  • Ms. Suzanne Hancock
    Chief Operations Officer
  • Dr. Randolph Corteling Ph.D.
    Chief Scientific Officer
  • Mr. Simon Dew
    Chief Business Officer

RENE Stock Analysis - Frequently Asked Questions

How have RENE shares performed this year?

ReNeuron Group's stock was trading at GBX 3.50 at the beginning of the year. Since then, RENE stock has decreased by 3.6% and is now trading at GBX 3.38.
View the best growth stocks for 2024 here
.

How were ReNeuron Group's earnings last quarter?

ReNeuron Group plc (LON:RENE) announced its quarterly earnings results on Monday, July, 20th. The company reported ($35.90) earnings per share for the quarter, topping analysts' consensus estimates of ($50.20) by $14.30.

How do I buy shares of ReNeuron Group?

Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR) and Sirius Minerals (SXX).

This page (LON:RENE) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners